Nathalie Trépo

Investor Relations Contact at SparingVision SAS

Health Technology

Profile

Nathalie Trépo is currently the Director-Investor Relations & Communications at SparingVision SAS since 2022.
Prior to this, she worked as the Head-Investor Relations at Theradiag SA and Neovacs SA.

Nathalie Trépo active positions

Companies	Position	Start
SparingVision SAS SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France.	Investor Relations Contact	2022-01-31

All active positions of Nathalie Trépo

Former positions of Nathalie Trépo

Companies	Position	End
THERADIAG	Investor Relations Contact	-
NEOVACS	Investor Relations Contact	-

See the detail of Nathalie Trépo's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Nathalie Trépo's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
NEOVACS	Health Technology

Private companies	2
Theradiag SA Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France.	Health Technology
SparingVision SAS SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France.	Health Technology